Category: Corporate News

Medicilon Debuts at CIIE, Connecting the World

Medicilon Debuts at CIIE

Medicilon showcased its comprehensive R&D services at the 9^th China International Import Expo (CIIE) in Shanghai, held from November 5-10, 2026. Featured in the Pudong New Area’s service trade pavilion, Medicilon highlighted its drug discovery, pharmaceutical, and preclinical research capabilities, aiming to expand global innovation partnerships.

Medicilon’s presence underscored the growing importance of service trade, with Medicilon specifically presenting its CRO service chain, including advanced NAMs-based strategies for regulatory submissions.

Ecosystem Partnerships

A key highlight was Dr. Xiaoyan Yuan’s presentation on November 8, detailing NAMs-based strategies for drug nonclinical safety. She emphasized the Center for Drug Evaluation’s “Pioneer Program” for New Approach Methodologies (NAMs), signaling a shift from academic exploration to regulatory implementation. Dr. Yuan advised companies to proactively align with CDE guidelines, build validation data, and engage in early communication for a competitive edge.

This reflects Medicilon’s strategic evolution, from forming an ecosystem partnership with Yaosu Technology at the 8th CIIE in 2025 to now sharing NAMs strategies. Medicilon’s continuous participation in CIIE demonstrates its commitment to transforming technological collaborations into robust platform capabilities.

Share an Open Future

Embracing the CIIE’s spirit of connectivity and openness, Medicilon’s theme, “Service Chains Connecting the World,” represents its ongoing efforts to meet international regulatory standards and integrate into the global innovation network. With nearly 700 IND clinical approvals supported and 27 innovative drugs licensed, Medicilon plans to continue utilizing platforms like CIIE to globalize more innovative drugs through its advanced preclinical R&D services.

Medicilon Debuts at CIIE, Connecting the World